A recent article by the New York Times looks at the often-overlooked connection between the abuse of prescription painkillers, such as hydrocodone and oxycodone, and later heroin use. Read more from the New York Times here.
A researcher publishing in the Journal of Clinical Oncology has found that patients with higher copayments were 70% more likely to stop taking Gleevec (imatinib) for their cancer, and patients were 42% more likely to skip doses entirely. Noting the importance of adherence for patients with chronic myeloid leukemia (CML), which drugs like Gleevec [...]
Brigham Young University Researchers examined the Twitter feeds of the university's students for mentions of the stimulant ADHD medication Adderall. They found 213,633 tweets from 132,099 unique users that mentioned the drug over a 6 month period. Students were most likely to mention the drug during exam periods, with mentions highest in the US Northeast [...]
Scientists writing in the Journal of Biological Chemistry have identified a new opioid receptor that may allow for more targeted pain and addiction treatments. Drugs targeting the kappa opioid receptor (KOR) would have the potential to increase therapeutic effects and minimize harmful side effects. Read more here.
The use of electronic monitoring was found to greatly improve medication adherence tracking over self-report alone in a clinical trial published in the journal Inflammatory Bowel Diseases. Researchers who conducted the study concluded that “In clinical studies involving patients with long-term chronic conditions, researchers should strongly consider collecting medication adherence data electronically, particularly where patients are [...]
A recent study published in the journal Patient Education and Counseling is among the first to examine how patients and primary care physicians discuss the risks of chronic opioid therapy, finding that a stronger therapeutic relationship was related to more thorough discussions. Read more here.
One day after recommending that hydrocodone-containing products be reclassified as more restricted Schedule II drugs, the FDA has approved Zohydro ER, the first hydrocodone-only formulation drug, developed by San Diego-based company Zogenix. The FDA's press release can be found here.
On Thursday the FDA recommended to the U.S. Department of Health and Human Services that hydrocodone containing drugs such as Vicodin be reclassified as Schedule II, rather than Schedule III drugs. The New York times has also reported on this substantial move by the FDA.
http://www.nytimes.com/2013/09/11/health/fda-announces-changes-to-labeling-of-some-prescription-painkillers.html?src=rechp The New York Times recently wrote on the opioid labeling changes announced by the FDA.
http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm367660.htm The FDA recently updated its labeling for extended-release (ER) opioids.